Jeffrey Lowe
4 statements across 2 episodes · 1 bullish · 0 bearish · 1 people on the record · first statement Apr 30, 2018 by Jeffrey Lowe · across every show →
On the record as a speaker too: Jeffrey Lowe's record, appearances and statements → this page counts the times other people say the name.
Everything said about Jeffrey Lowe, oldest first
Apr 30, 2018
Lowe: Unvalidated biotech platforms carry little value until an asset proves efficacy
“A unvalidated platform really doesn't have a lot of value, and that's why there's, On the first asset, you know, the whole company's value may be riding on this asset because not only is that asset in itself valuable, but it also validates the efficacy and use…”
Apr 30, 2018
Lowe: Tech-bio founders struggle to translate tech for traditional audiences
“I think it's about speaking a new language. So you have, you know, tech entrepreneurs and technical founders coming in and speaking a language. That is very geared toward a tech audience having a new technology, and I think what we're so interested in is bring…”
Jan 2, 2019 neutral
Lowe: Tech VC takes market risk, biotech VC takes scientific risk
“Traditionally, we've seen tech investing go for companies where the technical risk was quite low, but the market risk quite high. They're investing in growth, and they see profits over time. Biotech investors looking at places where a science risk is high, but…”
Jan 2, 2019 bullish
Lowe: Non-therapeutic CRISPR applications like diagnostics are just beginning
“I also think we're going to see a lot of interesting things in the non-therapeutic CRISPR space. So in a therapeutic CRISPR side, there are a bunch of public companies that are going directly after using CRISPR to cure disease. I think it's just the beginning …”